Abstract:Background: Cancer cachexia is a debilitating syndrome associated with marked body loss because of muscular atrophy and fat loss. There are several mechanisms contributing to the pathogenesis of cachexia. The presence of the tumor releases cytokines from inflammatory and immune cells, which play a significant role in activating and deactivating certain pathways associated with protein, carbohydrate, and lipid metabolism. This review focuses on various cascades involving an imbalance between protein synthesis and degradation in the skeletal muscles. Objectives: This study aimed to elucidate the mechanisms involved in skeletal muscle wasting phenomenon over the last few years. Methods: This article briefly overviews different pathways responsible for muscle atrophy in cancer cachexia. Studies published up to April 2023 were included. Important findings and study contributions were chosen and compiled using several databases including PubMed, Google Scholar, Science Direct, and ClinicalTrials.gov using relevant keywords. Results: Cancer cachexia is a complex disease involving multiple factors resulting in atrophy of skeletal muscles. Systemic inflammation, altered energy balance and carbohydrate metabolism, altered lipid and protein metabolism, and adipose tissue browning are some of the major culprits in cancer cachexia. Increased protein degradation and decreased protein synthesis lead to muscle atrophy. Changes in signaling pathway like ubiquitin-proteasome, autophagy, mTOR, AMPK, and IGF-1 also lead to muscle wasting. Physical exercise, nutritional supplementation, steroids, myostatin inhibitors, and interventions targeting on inflammation have been investigated to treat cancer cachexia. Some therapy showed positive results in preclinical and clinical settings, although more research on the efficacy and safety of the treatment should be done. Conclusion: Muscle atrophy in cancer cachexia is the result of multiple complex mechanisms; as a result, a lot more research has been done to describe the pathophysiology of the disease. Targeted therapy and multimodal interventions can improve clinical outcomes for patients.

The Pathway to Cancer Cachexia: MicroRNA-Regulated Networks in Muscle Wasting Based on Integrative Meta-Analysis

Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies

Modulating Metabolism to Improve Cancer-Induced Muscle Wasting

Cancer cachexia: molecular mechanisms and treatment strategies

Novel molecular targets of muscle wasting in cancer patients

Molecular Mechanisms of Cachexia: A Review

Cancer Cachexia: Signaling and Transcriptional Regulation of Muscle Catabolic Genes

Cancer Cachexia: Molecular Mechanism and Pharmacological Management

Molecular mechanisms of cancer cachexia‐induced muscle atrophy (Review)

Muscle wasting in cancer

Transcriptomic signature of cancer cachexia by integration of machine learning, literature mining and meta-analysis

Molecular mechanisms of cancer cachexia. Role of exercise training

Human Cachexia Induces Changes in Mitochondria, Autophagy and Apoptosis in the Skeletal Muscle

Myogenic microRNAs as Therapeutic Targets for Skeletal Muscle Mass Wasting in Breast Cancer Models

Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management

The Role of Non-Coding RNAs in Regulating Cachexia Muscle Atrophy

Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting

Mitophagy-mediated Inflammation and Oxidative Stress Contribute to Muscle Wasting in Cancer Cachexia

Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs

Decreased miR-497-5p Suppresses IL-6 Induced Atrophy in Muscle Cells

Circulating factors in cancer cachexia: recent opportunities for translational research